Anne Clem Whitaker
CIK 1593283 · Director · last filed 2026-10-09
Anne Clem Whitaker is a Director who has filed 37 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for ALKS, was dated Oct 9, 2026. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $284.6K across reported positions. 8 SEC filings were submitted jointly with Bausch Health Companies Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CREE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MORRISVILLE, NC 27560
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | — | $45.54 | — | $0 | 1 | 2026-10-09 |
| ICLR | Director | 958 | $203.01 | $194.5K | -$138.2K | 1 | 2026-08-12 |
| OSUR | Director | 26,163 | $3.44 | $90.1K | $0 | 3 | 2023-05-17 |
| LISATA THERAPEUTICS, INC. (CLBS) Delisted | Director | 12,176 | $6.40 | $77.9K | $0 | 3 | 2022-01-12 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 0 | $0.34 | $0 | -$2.7K | 4 | 2020-11-10 |
| WOLFSPEED, INC. (CREE) Delisted | Director | 11,274 | $79.12 | $892.0K | -$2.08M | 15 | 2020-11-06 |
| MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | President and CEO | 500,000 | — | — | $0 | 2 | 2015-03-04 |
Recent Filings
37 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-09 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2026-08-12 | ICLR | Mixed | +891 | -$138.2K | EDGAR |
| 2026-08-11 | ICLR | Notice (144) | −841 | -$138.2K | EDGAR |
| 2023-05-17 | OSUR | Tax (F) | −6,723 | -$37.0K | EDGAR |
| 2022-05-18 | OSUR | Grant (A) | +20,000 | $105.0K | EDGAR |
| 2022-01-12 | LISATA THERAPEUTICS, INC. (CLBS) Delisted | Grant (A) | +65,430 | $0 | EDGAR |
| 2021-11-10 | OSUR | Grant (A) | +10,563 | $105.0K | EDGAR |
| 2021-01-12 | LISATA THERAPEUTICS, INC. (CLBS) Delisted | Grant (A) | +37,735 | $0 | EDGAR |
| 2020-11-10 | Keenova Therapeutics plc (MNK) Delisted | Sell (S) | −21,087 | -$2.7K | EDGAR |
| 2020-11-06 | WOLFSPEED, INC. (CREE) Delisted | Mixed | −25,248 | -$1.76M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.